Navigation Links
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR

's anti-inflammatory and immunomodulatory activities without replicating its side effects. In phase 2 clinical trials, CRx-102 demonstrated a powerful anti-inflammatory effect and rapid onset of action in patients with osteoarthritis and rheumatoid arthritis, and was generally well tolerated. CRx-102 is being developed in a modified-release commercial formulation for the treatment of multiple immuno-inflammatory diseases.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates, their mechanisms of action and their clinical potential, its plans for clinical and formulation development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
4. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
5. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:7/4/2015)... July 4, 2015 ... eerstelijns chemotherapie voor patiënten met niet-resectabele uitgezaaide ... de progressievrije overleving in dat orgaan. ... kanker (mCRC) die alleen binnen de lever ... progressievrije overleving (PFS) in de lever dankzij ...
(Date:7/3/2015)... July 3, 2015 Un ... épidémies que sont l,hypertension, le diabète et les ... plateformes éducatives gratuites et d,une conférence majeure dédiée ... http://photos.prnewswire.com/prnh/20150630/227033 ) , Les formations ... , Prendre en charge l,hypertension en ligne ...
(Date:7/2/2015)... Pharma Major Lupin Limited ... en ZAO "Biocom" en Rusia bajo ciertas condiciones ... Lupin en el mercado farmacéutico de Rusia que ... como uno de los 10 principales mercados farmacéuticos ... de una década, el mercado farmacéutico ruso registró ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3
... medical robotic conference will convene Jan. 13-16, 2011 at ... together world leaders in robotic surgery and alternative therapies ... Hosted by the Henry Ford Vattikuti Urology Institute ... Symposium 2011 will showcase experts in robotic surgery who ...
... The National Community Pharmacists Association (NCPA) expressed strong ... launched by the U.S. Senate Special Committee on ... Pharmalot . (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... response, NCPA President Joseph H. Harmison, PD and Arlington, ...
Cached Medicine Technology:International Robotic Urology Symposium 2011 2NCPA Commends Senate Aging Committee for Launching CVS Caremark Investigation to Examine Alleged Harm to Seniors, Medicare 2
(Date:7/4/2015)... ... July 04, 2015 , ... ... published the results of an annual member survey , detailing the most ... More recently, the group broke that raw data down into charts detailing demographic ...
(Date:7/3/2015)... ... 03, 2015 , ... Brendon Burchard's new High Performance ... media attention. In an effort to spread the news, a comprehensive review of ... many people are feeling overwhelmed by stress and fatigue," reports Hendricks. "Many folks ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... healthcare providers, has been retained to lead a national president recruitment ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:7/3/2015)... ... 03, 2015 , ... Jennifer Renee Hanes, DO is the new Medical Director ... network of independent freestanding emergency rooms in the United States. , “We are excited ... facility,” said Executive Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. ...
(Date:7/3/2015)... ... 2015 , ... The Celebrity Dresses is currently running a promotion through July ... will have the opportunity to get 10% discount on orders that are over $100. ... have to use coupon codes or remember redemption codes. , There is a ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2
... 24 Opportunity International today,announced it has received a ... grant to design, create and implement new electronic,and mobile ... services available to more people in Sub-Saharan Africa. , ... firm started by eBay founder,Pierre Omidyar and his wife ...
... Avon Foundation Breast Cancer Forum Focuses on Research & ... More than 100 scientists and clinicians from the U.S., ... discuss the latest in breast cancer research and prevention ... was sponsored this year by Novartis Oncology, sanofi-aventis U.S., ...
... February 24, 2009) David H. Adams, MD, ... the Department of Cardiothoracic Surgery at The Mount Sinai ... Carpentier-Edwards Physio II ring in the United States yesterday. ... the Food and Drug Administration last month, with Alain ...
... climber scaling 94 flights in 9 minutes, 31 secondsCHICAGO, Feb. ... Hustle up the Hancock stair climb event on Sunday, February ... the fight against lung disease, the third leading cause of ... is expected to raise more than $1 million to benefit ...
... high-availability failover support. , ... (PRWEB) February 24, 2009 ... latest version of the industry leading digital signage platform, CoolSign 4.3., ... existing enterprise-based, robust feature set, adding new key enhancements to the ...
... to five melanoma researchers-HILLSBOROUGH, N.J., Feb. 24 ... independent, national organization devoted to melanoma in the ... grants as part of its Career Development Grant ... MRF,s Research Grant Programs support promising medical research ...
Cached Medicine News:Health News:Omidyar Network Grants $4.5 Million to Opportunity International to Scale Technology-based Microfinance Services in Africa 2Health News:Omidyar Network Grants $4.5 Million to Opportunity International to Scale Technology-based Microfinance Services in Africa 3Health News:Omidyar Network Grants $4.5 Million to Opportunity International to Scale Technology-based Microfinance Services in Africa 4Health News:Avon Foundation Convened Breast Cancer Experts in Miami to Address Prevention Strategies at Annual Forum 2Health News:Avon Foundation Convened Breast Cancer Experts in Miami to Address Prevention Strategies at Annual Forum 3Health News:Over 4,000 Hustle Up the Hancock to Fight Lung Disease 2Health News:Non-Profit Gives $800,000 for Melanoma Research in 2009 2Health News:Non-Profit Gives $800,000 for Melanoma Research in 2009 3
... These blades are designed for the retraction ... well as the brain. Equalizes brain retraction pressure. ... of retractor. Used in conjunction with the Budde ... to 1" wide and 2 mm and 4 ...
... designed for the retraction of nerves, vessels, tissue, ... Equalizes brain retraction pressure. Decreases shear injury to ... conjunction with the Budde Halo Retractor. Range of ... 2 mm and 4 mm wide. Quick change ...
Epstein Curettes 3.0 mm, length 8" (203 mm)....
Semmes Spinal Fusion Curettes, length 9" (229 mm), ring size 4 x 7 mm....
Medicine Products: